Clinical Trial Manager
I originally trained as a Biochemist, and have been working in healthcare research since 1999. Initially I worked as a research assistant in the Diabetes Trials Unit in Oxford. After completing a DPhil in Immunology, investigating the Varicella Zoster Virus. I moved back into clinical trials.
I joined the Department on 2010 as a Clinical Trial Co-ordinator, initially working on the MAC trial, investigating the use of Montelukast in post-infectious cough in adults, and the CAPS study, looking at the epidemiology of persistent cough in children.
Subsequently, I joined the Health Behaviours & other conditions theme, as trial manager for the EDGE study, investigating self-monitoring in people with COPD. Alongside this I ran a the Oxford arm of the MASTERMIND study, investigating how people responded to different diabetes medication and their medication adherence.
I have also been involved in various stages of a number of other trials including, POC HbA1c, CANDID, TasminH4, StAR-2D and Summit-D.
I am currently a member of the Cardiovascular and Renal Theme. I am working with Professor Richard Hobbs managing the BARACK-D Trial, which investigates the use of Spironolactone in patients with Chronic Kidney Disease.
I am also working with Professor Rafael Perera, as trial manager for the FORM2C study, investigating the optimal frequency of testing, and the use of different test to monitor kidney function.
I am a member of the UK Trial Managers Network and for since2015 I have taught clinical trial management for the University of Oxford and a lecturer and facilitator on the Clinical Trials Management module.
On-site monitoring of primary outcomes is important in primary care clinical trials: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK-D) Trial a case study
Jones L. et al, (2019), TRIALS, 20
Farmer A. et al, (2017), Journal of Medical Internet Research, 19
The role of Der p 1 specific T cells in atopic eczema
Chan HW. et al, (2013), AUSTRALASIAN JOURNAL OF DERMATOLOGY, 54, 13 - 14
Crack LR. et al, (2012), Clinical and Experimental Dermatology, 37, 534 - 543
Human antimicrobial peptides LL-37 and human β-defensin-2 reduce viral replication in keratinocytes infected with varicella zoster virus
Crack LR. et al, (2012), Clinical and Experimental Dermatology